The 2022 Congress of the European Society of Cardiology brought together just over 30,000 cardiovascular health professionals from 174 countries. A total of 36 studies were presented with topic such as imaging, digital health and artificial intelligence aimed at antithrombotic therapy, invasive cardiology, and of course, the impact of COVID-19 on heart health.
Another remarkable aspect is that, in addition to the clinical trials sponsored by companies, such as DELIVER, PERSPECTIVE and 3 phase II studies on factor XI inhibitors, there were also many other trials initiated by researchers. Among them we can mention TIME, SECURE, DANCANVAS, INVICTUS AND REVIVED; these trials address relevant clinical questions and satisfy unmet needs.
On the other hand, it is worth noting that, for the first time, during the ESC Congress 2022 the following Guides were released (click on each name to see the original document):
2022 ESC Guidelines on cardio-oncology
ESC 2022 Clinical Trials
ESC 2022 Clinical Trials
We offer you a summary of 5 of the most anticipated trials that were presented at the 2022 Congress of the European Society of Cardiology, so that you have an overview of the advances and results.
TIME
Objective: To investigate if evening administration of antihypertensives improves their protective effects against heart attack, stroke, and vascular death.
TIME Result: The time of day does not affect the outcome. It is suggested that patients take the drug at the time that is most convenient for them or that best minimizes unwanted effects.
DELIVER
Objective: To identify whether dapaglifozin reduces cardiovascular morbidity and mortality in patients with heart failure and mildly reduced or preserved EF.
DELIVER Result:Dapaglifozin reduces the risk of cardiovascular death or worsening heart failure in patients with reduced and preserved ejection fraction.
REVIVED
Objective: First randomized study to determine the efficacy and safety of Percutaneous Coronary Intervention (PCI) in patients with left ventricular systolic dysfunction (LVSD).
REVIVED Outcome: PCI does not reduce mortality or heart failure hospitalization in patients with LVDS and extensive coronary artery disease.
INVICTUS
Objective: To compare rivaroxaban vs. vitamin K antagonists in patients with rheumatic heart disease, atrial fibrillation, and elevated stroke risk.
INVICTUSResult: Vitamin K antagonists reduce the risk of cardiovascular events and mortality in rheumatic heart disease patients with atrial fibrillation, without increasing the risk of bleeding.
SECURE
Objective: First randomized trial to determine the impact of a polypill on recurrent cardiovascular events in post MI patients.
SECURE Result: The polypill used in the trial contained acetylsalicylic acid and drugs to lower lipid level and blood pressure. This combination was shown to be more effective in preventing future adverse cardiovascular events after MI, than taking those drugs separately.
Source: European Society of Cardiology
